{"pmid":32363963,"title":"Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case-report.","text":["Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case-report.","J Dermatolog Treat","Daneshpazhooh, Maryam","Soori, Tahereh","Isazade, Ahdie","Noormohammadpour, Pedram","32363963"],"journal":"J Dermatolog Treat","authors":["Daneshpazhooh, Maryam","Soori, Tahereh","Isazade, Ahdie","Noormohammadpour, Pedram"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363963","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/09546634.2020.1764472","keywords":["covid-19","ivig","mucous membrane pemphigoid"],"topics":["Case Report"],"weight":1,"_version_":1666138496060882944,"score":9.490897,"similar":[{"pmid":32361195,"title":"SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?","text":["SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?","Autoimmun Rev","Prete, Marcella","Favoino, Elvira","Catacchio, Giacomo","Racanelli, Vito","Perosa, Federico","32361195"],"journal":"Autoimmun Rev","authors":["Prete, Marcella","Favoino, Elvira","Catacchio, Giacomo","Racanelli, Vito","Perosa, Federico"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361195","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102559","keywords":["autoinflammatory syndrome","caps","capillary leakage syndrome","il-6","ivig","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495915130880,"score":105.85265},{"pmid":32258207,"pmcid":"PMC7111600","title":"High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.","text":["High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.","The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.","Open Forum Infect Dis","Cao, Wei","Liu, Xiaosheng","Bai, Tao","Fan, Hongwei","Hong, Ke","Song, Hui","Han, Yang","Lin, Ling","Ruan, Lianguo","Li, Taisheng","32258207"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19."],"journal":"Open Forum Infect Dis","authors":["Cao, Wei","Liu, Xiaosheng","Bai, Tao","Fan, Hongwei","Hong, Ke","Song, Hui","Han, Yang","Lin, Ling","Ruan, Lianguo","Li, Taisheng"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32258207","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1093/ofid/ofaa102","keywords":["coronavirus disease 2019","high-dose intravenous immunoglobulin","immunomodulation"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138493090267136,"score":85.56615},{"pmid":32218340,"pmcid":"PMC7178250","title":"Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?","text":["Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?","The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen Candida albicans in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 degrees C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available.","Int J Mol Sci","Jawhara, Samir","32218340"],"abstract":["The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen Candida albicans in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 degrees C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available."],"journal":"Int J Mol Sci","authors":["Jawhara, Samir"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32218340","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.3390/ijms21072272","keywords":["ivig","coronavirus","immunotherapy","ncov-2019","virus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138492290203648,"score":84.801315},{"pmid":32432784,"title":"Editorial - High dose intravenous immunoglobulins as a therapeutic option for COVID-19 patients.","text":["Editorial - High dose intravenous immunoglobulins as a therapeutic option for COVID-19 patients.","Eur Rev Med Pharmacol Sci","Scoppetta, C","Di Gennaro, G","Polverino, F","32432784"],"journal":"Eur Rev Med Pharmacol Sci","authors":["Scoppetta, C","Di Gennaro, G","Polverino, F"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32432784","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.26355/eurrev_202005_21214","topics":["Treatment"],"weight":1,"_version_":1667342288299229184,"score":74.60492},{"pmid":32426229,"pmcid":"PMC7229478","title":"Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia.","text":["Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia.","We describe a 42-year old woman, admitted to our Department after 15 days of persistence of respiratory failure and treated with infusion of intravenous immunoglobulin with a successful outcome.","IDCases","Lanza, Maurizia","Polistina, Giorgio Emanuele","Imitazione, Pasquale","Annunziata, Anna","Di Spirito, Valentina","Novella, Carannante","Fiorentino, Giuseppe","32426229"],"abstract":["We describe a 42-year old woman, admitted to our Department after 15 days of persistence of respiratory failure and treated with infusion of intravenous immunoglobulin with a successful outcome."],"journal":"IDCases","authors":["Lanza, Maurizia","Polistina, Giorgio Emanuele","Imitazione, Pasquale","Annunziata, Anna","Di Spirito, Valentina","Novella, Carannante","Fiorentino, Giuseppe"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426229","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.idcr.2020.e00794","keywords":["covid 19","immunoglobulin","pandemia","pneumoniae","respiratory failure"],"topics":["Case Report"],"weight":1,"_version_":1667252837972705280,"score":68.95141}]}